



ROTAVIRUS

COMMON, SEVERE, DEVASTATING, PREVENTABLE

[THE LATEST EVIDENCE &
WHAT'S NEEDED TO STOP
ILLNESSES AND DEATHS]

EXECUTIVE SUMMARY



Rotavirus Organization of Technical Allies

ROTACOUNCIL.ORG




Overview

Diarrhea is one of the world's leading causes of child illness and death, and rotavirus is the most common cause of severe diarrhea. Every child everywhere is vulnerable. Each year, rotavirus diarrhea kills about 200,000 children in countries around the world (1, 2) and hospitalizes hundreds of thousands more, despite the fact that safe, effective vaccines exist that can protect children from this disease.

Rotavirus is highly contagious, and every child is at risk. Infants and children under the age of 2 years face the greatest risk of infection. Rotavirus causes gastroenteritis, an inflammation of the stomach and intestines. It primarily infects the small intestine, destroying the surface tissue and preventing the absorption of nutrients, causing diarrhea (4). Typical symptoms can range from mild, watery diarrhea to severe diarrhea with vomiting and fever.

FIGURE 1: Global Diarrhea Hospitalizations (2, 3)



While mild to moderate dehydration caused by rotavirus infections can be treated with oral rehydration therapy (ORT), children who develop severe dehydration often require intravenous fluids (which can be given in outpatient centers) and hospitalization. Despite the fact that ORT is inexpensive and effective, many of the world's poorest children do not have access to it. In fact, ORT coverage is only about 30% in many of the places where the most diarrhea deaths occur (5). And without access to ORT or the urgent medical care severe infections require, rotavirus can be deadly.

High disease burden

Two out of every five diarrhea-related hospitalizations among children under age 5 are caused by rotavirus (2, 3)—it is not your typical “stomach bug” or “flu.” For those who survive, rotavirus infections can have a lasting impact:

- It can take up to two months for the intestine to fully repair itself after a moderate-to-severe case of rotavirus. As the intestine repairs, children cannot absorb nutrients as well, which means that during crucial stages of development, they grow significantly less than children who have not been sick with rotavirus diarrhea (6).
- Children who suffer from an episode of moderate-to-severe diarrhea—from infections like rotavirus—are weakened and malnourished. They are more susceptible to the next illness that strikes, and have a more than eight-fold increase in their risk of death from any cause in the two to three months following an episode of diarrhea (6).
- Treating rotavirus is expensive. In Bangladesh, treating just one episode of rotavirus can amount to nearly 85% of the average family’s monthly income (7). In Malaysia, rotavirus hospitalization costs more than one quarter of the average monthly income (8). In Uganda, the cost for inpatient admission for one episode of severe rotavirus diarrhea amounts to 10% of the average family’s monthly income (9, 10).

Because children can become infected with rotavirus and other causes of diarrhea more than once, preventing illness in the first place is critical.

Rotavirus vaccines save lives and improve health

There are two World Health Organization (WHO) prequalified, orally administered rotavirus vaccines available today: Rotarix[®], manufactured by GlaxoSmithKline, and RotaTeq[®], manufactured by Merck & Co., Inc. Both vaccines have been shown to be safe and effective in large-scale clinical studies in Asia, Africa, the Americas and Europe. Based on this

The impact of the two currently licensed vaccines on severe rotavirus and all-cause diarrhea has been dramatic in countries that have introduced the vaccine.

body of research, WHO recommends that all countries introduce rotavirus vaccines into their national immunization programs. New rotavirus vaccines are in development in many countries. ROTAVAC®, manufactured by Bharat Biotech, was licensed in India in January 2014 and introduced into India’s private market in March 2015; it could receive WHO prequalification by 2018.

- Rotavirus vaccines are already saving lives and improving health in the countries where they are in use, with countries in every region of the world reporting major reductions in hospitalizations and deaths due to severe diarrhea (11).
- Rotavirus vaccines have been shown to provide broad protection, even against strains not included in the vaccine (12-17).
- Rotavirus vaccines have also been shown to reduce hospitalization from all-cause diarrhea (18-29).
- They have also been shown to reduce rotavirus-related hospitalizations among children and adults who are too old to be vaccinated—providing herd immunity (30-40).
- The benefits of vaccination are substantial and far exceed any low-level risk associated with vaccination (41-43). While most children do not experience any side effects following vaccination, there is a slight chance of minor symptoms including diarrhea, vomiting and irritability. In extremely rare cases, intussusception, a bowel blockage, may occur.

Unlike other forms of diarrhea, improvements in water, sanitation and hygiene alone do not adequately prevent the spread of rotavirus. Vaccination is the best way to protect children, and rotavirus vaccines are essential to a comprehensive approach to preventing and treating diarrhea.

Not only does vaccination reduce the health burden of rotavirus, it also reduces the economic burden that families face when their children get sick.

The cost-effectiveness of rotavirus vaccines has been evaluated in numerous studies in low-, middle- and high-income countries. Rotavirus vaccines are projected to be highly cost-effective, particularly in regions suffering from the highest levels of rotavirus mortality (44).

FIGURE 2: Real-world impact: rotavirus hospitalizations reduced by half or more

COUNTRY	VACCINE USED	VACCINE IMPACT: REDUCTION IN HOSPITALIZATIONS
Australia	Rotarix, RotaTeq	45-88%
Austria	Rotarix, RotaTeq	74-79%
Belgium	Rotarix, RotaTeq	50-80%
El Salvador	Rotarix	69-86%
Finland	RotaTeq	78%
USA	Rotarix, RotaTeq	55-94%

Source: PATH summary of impact studies:
<http://sites.path.org/rotavirusvaccine/vaccine-impact-data>

Note: Studies vary in time period and age group, and therefore are not directly comparable. However, when taken together, they demonstrate the significant impact of the vaccine.

FIGURE 3: Reductions in deaths in early adopter countries

COUNTRY	ROTAVIRUS VACCINE INTRODUCTION YEAR	REDUCTION IN ALL-CAUSE GASTROENTERITIS DEATHS AMONG CHILDREN UNDER AGE 5 FOLLOWING INTRODUCTION
Bolivia	2008	36-43%
Brazil	2006	22%
El Salvador	2006	0-36%
Honduras	2009	16-20%
Mexico	2007	43-55%*
Panama	2006	50%**
Venezuela	2006	57-64%

References: 19, 27, 29, 45

*Measured from 2009-2011. While methodologies differ, and some studies aren't directly comparable, it is clear the vaccine has had a significant impact.

**Among children aged 0-4


WHO recommends that rotavirus vaccines be introduced into every country's national immunization program, particularly those where diarrhea is a leading cause of child death (46).

While at least 80 countries have introduced rotavirus vaccines nationally, more than 100 have not. Very few countries in Asia have introduced the vaccine. Over 94 million infants lack access to rotavirus vaccines (47). Less than 25% of infants in Gavi-eligible countries currently have access to the vaccine (47).

More must be done to reach children living in the places where diarrhea, such as rotavirus, is a major public health issue.

Millions of illnesses and tens of thousands of deaths could be prevented through rotavirus vaccination.

FIGURE 4: Countries that have introduced rotavirus vaccines as of December 2015





Integrated Global Action Plan for the Prevention and Control of Pneumonia and Diarrhea (GAPPD)

Prevention, protection and treatment make up the framework of the GAPPD, a 2013 global plan from UNICEF and

WHO and endorsed by the ROTA Council (48). The GAPPD represents the first-ever effort to protect children simultaneously from pneumonia and diarrhea. Rotavirus vaccines are essential to a comprehensive approach to fighting diarrhea, which consists of:

- **Treatment.** When children do become sick with rotavirus, mild to moderate cases can be treated with oral rehydration solution (ORS)—which is a simple mixture of appropriately constituted electrolytes and water—and with zinc supplements and appropriate case management. However, diarrhea that results in severe dehydration may require IV fluids and urgent medical care. Rotavirus cannot be treated with antibiotics or other drugs.
- **Prevention.** Rotavirus vaccines are the best tool available today to prevent rotavirus. Rotavirus vaccines are a critical tool in fighting rotavirus because improvements in drinking water, sanitation and hygiene, which can prevent other forms of diarrhea, do not adequately prevent the spread of rotavirus.
- **Protection.** Good health practices can help protect children from diarrhea. These practices include exclusive breastfeeding for the first six months of a baby's life and providing appropriate complementary feeding after six months.



Conclusion

Rotavirus is the most common cause of severe diarrhea, and every child is vulnerable. Vaccines are safe, effective and the most powerful tool to protect children from rotavirus. In countries where they are in use, vaccines are already saving the lives and improving the health of countless numbers of children. Despite the WHO recommendation that rotavirus vaccines be introduced into every country's national immunization program, 94 million infants still do not have access to this critical intervention. These countries should prioritize the vaccines now—millions of illnesses and tens of thousands of deaths can be prevented through rotavirus vaccination.

Recommendations for global action to prevent rotavirus illnesses and deaths

The ROTA Council strongly endorses the recommendation by WHO that all countries introduce rotavirus vaccines. In addition, to accelerate the introduction of lifesaving, health-improving rotavirus vaccines, the ROTA Council recommends that key stakeholders undertake actions in the following areas:

- **Gavi-eligible countries** that have not yet introduced rotavirus vaccines into their childhood immunization schedules should strongly consider applying to Gavi for new vaccine support for rotavirus vaccine as soon as possible.
- **Governments and funding agencies** should continue to support the research and development of new, low-cost rotavirus vaccines using public, social business and public-private models. Emerging market manufacturers have demonstrated the ability to develop and license low-cost rotavirus vaccines (Rotavin and ROTAVAC®) with technology transfer and public funding support.
- **Global health entities** (e.g. UNICEF, WHO, Gavi) **and NGOs influential in vaccine programs** (e.g., Médecins Sans Frontières and Save the Children) should expedite initiatives to ensure prices paid for rotavirus vaccines reflect true manufacturing costs, provide reasonable returns on manufacturers' investment and take into account an individual country's ability to pay. Additional mechanisms may be required to provide innovative funding options for low-middle income, non-Gavi eligible countries. To enable countries of all income groups to include rotavirus vaccines in their national immunization programs, transparent and flexible pricing mechanisms are required.
- **National governments, global health entities, funding agencies, manufacturers and other stakeholders** should facilitate the development of new, live oral vaccines that address barriers to global supply for Gavi and low- and middle-income countries; implementation challenges (cold chain, volume of administration and storage, delivery systems, safety concerns) and cultural sensitivity; and that are safe, efficacious and available at low cost.
- In conjunction with the introduction of rotavirus vaccine, **countries should work with WHO, UNICEF and other partners** to plan and implement a comprehensive set of interventions to reduce illnesses and deaths from diarrheal disease, consistent with the GAPPD.

References

1. Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, et al. Global burden of childhood pneumonia and diarrhoea. *Lancet*. 2013;381(9875):1405-16.
2. Lanata CF, Fischer-Walker CL, Olascoaga AC, Torres CX, Aryee MJ, Black RE, et al. Global causes of diarrheal disease mortality in children <5 years of age: a systematic review. *PLoS One*. 2013;8(9):e72788.
3. Parashar UD, Gibson CJ, Bresee JS, Glass RI. Rotavirus and severe childhood diarrhea. *Emerg Infect Dis*. 2006;12(2):304-6.
4. Estes MK, Kapikian AZ. Rotaviruses. In: Nriye R, Howley PM, Griffin D, Lamb R, Martin M, Roizman B, editors. *Fields virology*, vol 1. Philadelphia (EUA): : Lippincott Williams & Wilkins; 2001.
5. Santosham M, Chandran A, Fitzwater S, Fischer-Walker C, Baqui AH, Black R. Progress and barriers for the control of diarrhoeal disease. *Lancet*. 2010;376(9734):63-7.
6. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Faraq TH, Panchalingam S, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. *Lancet*. 2013;382(9888):209-22.
7. icddr b. Preliminary analysis from "The economic burden of rotavirus infection resulting in hospitalization among children <5 years of age in selected hospitals of Bangladesh". icddr,b Protocol# 14009.
8. Chai PL, WS. Out-of-pocket costs associated with rotavirus gastroenteritis requiring hospitalization in Malaysia. *Vaccine*. 2009;27(5):F112-F115. *Vaccine*. 2009;27(5):F112-F5.
9. Sigei C, Odaga J, Mvundura M, Madrid Y, Clark AD, Kenya ProVac Technical Working G, et al. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda. *Vaccine*. 2015;33 Suppl 1:A109-18.
10. Statistics UBo. Uganda National Household Surveys Report 2009/2010: Main source of household earning.
11. Tate JE, Parashar UD. Rotavirus vaccines in routine use. *Clin Infect Dis*. 2014;59(9):1291-301.
12. Patel MM, Glass R, Desai R, Tate JE, Parashar UD. Fulfilling the promise of rotavirus vaccines: how far have we come since licensure? *Lancet Infect Dis*. 2012;12(7):561-70.
13. Steele AD, Neuzil KM, Cunliffe NA, Madhi SA, Bos P, Ngwira B, et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. *BMC Infect Dis*. 2012;12:213.
14. Nakagomi T, Nakagomi O, Dove W, Doan YH, Witte D, Ngwira B, et al. Molecular characterization of rotavirus strains detected during a clinical trial of a human rotavirus vaccine in Blantyre, Malawi. *Vaccine*. 2012;30 Suppl 1:A140-51.
15. De Vos B, Han HH, Bouckenooghe A, Debrus S, Gillard P, Ward R, et al. Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes: integrated analysis of randomized controlled trials. *Pediatr Infect Dis J*. 2009;28(4):261-6.
16. Chandran A, Fitzwater S, Zhen A, Santosham M. Prevention of rotavirus gastroenteritis in infants and children: rotavirus vaccine safety, efficacy, and potential impact of vaccines. *Biologics*. 2010;4:213-29.
17. Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2010;376(9741):606-14.
18. Yen C, Armero Guardado JA, Alberto P, Rodriguez Araujo DS, Mena C, Cuellar E, et al. Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador. *Pediatr Infect Dis J*. 2011;30(1 Suppl):S6-S10.
19. do Carmo GM, Yen C, Cortes J, Siqueira AA, de Oliveira WK, Cortez-Escalante JJ, et al. Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis. *PLoS Med*. 2011;8(4):e1001024.
20. Safadi MA, Berezin EN, Munford V, Almeida FJ, de Moraes JC, Pinheiro CF, et al. Hospital-based surveillance to evaluate the impact of rotavirus vaccination in Sao Paulo, Brazil. *Pediatr Infect Dis J*. 2010;29(11):1019-22.
21. Gurgel RG, Bohland AK, Vieira SC, Oliveira DM, Fontes PB, Barros VF, et al. Incidence of rotavirus and all-cause diarrhea in northeast Brazil following the introduction of a national vaccination program. *Gastroenterology*. 2009;137(6):1970-5.
22. Molto Y, Cortes JE, De Oliveira LH, Mike A, Solis I, Suman O, et al. Reduction of diarrhea-associated hospitalizations among children aged < 5 Years in Panama following the introduction of rotavirus vaccine. *Pediatr Infect Dis J*. 2011;30(1 Suppl):S16-20.
23. Quintanar-Solares M, Yen C, Richardson V, Esparza-Aguilar M, Parashar UD, Patel MM. Impact of rotavirus vaccination on diarrhea-related hospitalizations among children < 5 years of age in Mexico. *Pediatr Infect Dis J*. 2011;30(1 Suppl):S11-5.

24. Msimang VM, Page N, Groome MJ, Moyes J, Cortese MM, Seheri M, et al. Impact of rotavirus vaccine on childhood diarrheal hospitalization after introduction into the South African public immunization program. *Pediatr Infect Dis J*. 2013;32(12):1359-64.
25. Richardson V, Hernandez-Pichardo J, Quintanar-Solares M, Esparza-Aguilar M, Johnson B, Gomez-Altamirano CM, et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. *N Engl J Med*. 2010;362(4):299-305.
26. Richardson V, Parashar U, Patel M. Childhood diarrhea deaths after rotavirus vaccination in Mexico. *N Engl J Med*. 2011;365(8):772-3.
27. Gastanaduy PA, Sanchez-Uribe E, Esparza-Aguilar M, Desai R, Parashar UD, Patel M, et al. Effect of rotavirus vaccine on diarrhea mortality in different socioeconomic regions of Mexico. *Pediatrics*. 2013;131(4):e1115-20.
28. Lanzieri TM, Linhares AC, Costa I, Kolhe DA, Cunha MH, Ortega-Barria E, et al. Impact of rotavirus vaccination on childhood deaths from diarrhea in Brazil. *Int J Infect Dis*. 2011;15(3):e206-10.
29. Bayard V, DeAntonio R, Contreras R, Tinajero O, Castrejon MM, Ortega-Barria E, et al. Impact of rotavirus vaccination on childhood gastroenteritis-related mortality and hospital discharges in Panama. *Int J Infect Dis*. 2012;16(2):e94-8.
30. Begue RE, Perrin K. Reduction in gastroenteritis with the use of pentavalent rotavirus vaccine in a primary practice. *Pediatrics*. 2010;126(1):e40-5.
31. Buttery JP, Lambert SB, Grimwood K, Nissen MD, Field EJ, Macartney KK, et al. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule. *Pediatr Infect Dis J*. 2011;30(1 Suppl):S25-9.
32. Paulke-Korinek M, Kollaritsch H, Aberle SW, Zwazl I, Schmidle-Loss B, Vecsei A, et al. Sustained low hospitalization rates after four years of rotavirus mass vaccination in Austria. *Vaccine*. 2013;31(24):2686-91.
33. Zeller M, Rahman M, Heylen E, De Coster S, De Vos S, Arijis I, et al. Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. *Vaccine*. 2010;28(47):7507-13.
34. Dey A, Wang H, Menzies R, Macartney K. Changes in hospitalisations for acute gastroenteritis in Australia after the national rotavirus vaccination program. *Med J Aust*. 2012;197(8):453-7.
35. Lambert SB, Faux CE, Hall L, Birrell FA, Peterson KV, Selvey CE, et al. Early evidence for direct and indirect effects of the infant rotavirus vaccine program in Queensland. *Med J Aust*. 2009;191(3):157-60.
36. Pendleton A, Galic M, Clarke C, Ng SP, Ledesma E, Ramakrishnan G, et al. Impact of rotavirus vaccination in Australian children below 5 years of age: a database study. *Hum Vaccin Immunother*. 2013;9(8):1617-25.
37. Shui IM, Baggs J, Patel M, Parashar UD, Rett M, Belongia EA, et al. Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants. *JAMA*. 2012;307(6):598-604.
38. Snelling TL, Andrews RM, Kirkwood CD, Culvenor S, Carapetis JR. Case-control evaluation of the effectiveness of the G1P[8] human rotavirus vaccine during an outbreak of rotavirus G2P[4] infection in central Australia. *Clin Infect Dis*. 2011;52(2):191-9.
39. Lopman BA, Curns AT, Yen C, Parashar UD. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. *J Infect Dis*. 2011;204(7):980-6.
40. Gastanaduy PA, Curns AT, Parashar UD, Lopman BA. Gastroenteritis hospitalizations in older children and adults in the United States before and after implementation of infant rotavirus vaccination. *JAMA*. 2013;310(8):851-3.
41. WHO. Update on intussusception following rotavirus vaccine administration: World Health Organization. Available from: http://www.who.int/vaccine_safety/committee/topics/rotavirus/rotarix_and_rotateq/dec_2013/en/.
42. WHO. Introduction of Rotavirus Vaccines: Information for Policy Makers, Programme Managers, and Health Workers. [Accessed January 19, 2015]. Available from: http://apps.who.int/iris/bitstream/10665/90374/1/WHO_IVB_13.08_eng.pdf.
43. WHO. Global Advisory Committee on Vaccine Safety, 11-12 December 2013. 2014 Feb 14. Report No.: 0049-8114 (Print), 0049-8114 Contract No.: 7.
44. Clark A, Jauregui B, Griffiths U, Janusz CB, Bolanos-Sierra B, Hajjeh R, et al. TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination. *Vaccine*. 2013;31 Suppl 3:C19-29.
45. De Oliveira LH, Giglio N, Ciapponi A, Garcia Marti S, Kuperman M, Sanwogou NJ, et al. Temporal trends in diarrhea-related hospitalizations and deaths in children under age 5 before and after the introduction of the rotavirus vaccine in four Latin American countries. *Vaccine*. 2013;31(Suppl 3):C99-C108.
46. WHO. Meeting of the immunization Strategic Advisory Group of Experts, April 2009—conclusions and recommendations. *Wkly Epidemiol Rec*. 2009;84(23):220-36.
47. IVAC. VIMS Report: Global Vaccine Introduction, September 2015. International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, 2015.
48. UNICEF, WHO. Ending Preventable Child Deaths from Pneumonia and Diarrhoea by 2025: The integrated Global Action Plan for Pneumonia and Diarrhoea (GAPPD). 2013 [Accessed January 19, 2015]. Available from: http://apps.who.int/iris/bitstream/10665/79200/1/9789241505239_eng.pdf?ua=1

Photos courtesy of the Bill & Melinda Gates Foundation

